Synlogic Inc (NASDAQ:SYBX) – Equities research analysts at Wedbush issued their FY2023 earnings per share (EPS) estimates for shares of Synlogic in a research note issued to investors on Wednesday, March 13th. Wedbush analyst D. Nierengarten anticipates that the biotechnology company will post earnings of $1.32 per share for the year.
SYBX has been the topic of a number of other research reports. Chardan Capital reissued a “buy” rating and issued a $20.00 price target on shares of Synlogic in a report on Tuesday. BTIG Research began coverage on shares of Synlogic in a report on Tuesday, February 12th. They issued a “buy” rating and a $22.00 price target on the stock. Zacks Investment Research raised shares of Synlogic from a “hold” rating to a “buy” rating and set a $9.75 price target on the stock in a report on Saturday, November 17th. ValuEngine raised shares of Synlogic from a “hold” rating to a “buy” rating in a report on Tuesday, December 11th. Finally, HC Wainwright set a $20.00 price target on shares of Synlogic and gave the stock a “buy” rating in a report on Monday, December 10th. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Synlogic currently has an average rating of “Buy” and an average target price of $18.59.
Shares of NASDAQ:SYBX opened at $7.73 on Friday. The firm has a market capitalization of $197.99 million, a PE ratio of -3.81 and a beta of 2.38. Synlogic has a one year low of $5.75 and a one year high of $14.59.
Synlogic (NASDAQ:SYBX) last announced its quarterly earnings results on Tuesday, March 12th. The biotechnology company reported ($0.47) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.56) by $0.09. The company had revenue of $0.11 million for the quarter, compared to analysts’ expectations of $0.24 million. Synlogic had a negative net margin of 1,922.02% and a negative return on equity of 35.58%.
In related news, insider Paul Francis Miller sold 9,000 shares of the stock in a transaction on Wednesday, February 13th. The shares were sold at an average price of $9.75, for a total transaction of $87,750.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 23.30% of the stock is currently owned by company insiders.
Several hedge funds have recently added to or reduced their stakes in SYBX. NEA Management Company LLC purchased a new stake in Synlogic during the 3rd quarter valued at $60,100,000. BlackRock Inc. boosted its position in Synlogic by 33.4% during the 4th quarter. BlackRock Inc. now owns 1,248,355 shares of the biotechnology company’s stock valued at $8,750,000 after buying an additional 312,398 shares during the period. Aquilo Capital Management LLC purchased a new stake in Synlogic during the 3rd quarter valued at $14,182,000. Vanguard Group Inc. purchased a new stake in Synlogic during the 3rd quarter valued at $9,958,000. Finally, Vanguard Group Inc purchased a new stake in Synlogic during the 3rd quarter valued at $9,958,000. 84.85% of the stock is currently owned by institutional investors.
Synlogic, Inc a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy, which is in Phase I clinical trial for the treatment of patients with liver disease and hepatic encephalopathy, and urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria.
Recommended Story: Understanding Compound Annual Growth Rate (CAGR)
Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.